Search results
Results from the WOW.Com Content Network
Normal pressure hydrocephalus (NPH), also called malresorptive hydrocephalus, is a form of communicating hydrocephalus in which excess cerebrospinal fluid (CSF) builds up in the ventricles, leading to normal or slightly elevated cerebrospinal fluid pressure.
Nephronophthisis is a genetic disorder of the kidneys which affects children. [3] It is classified as a medullary cystic kidney disease.The disorder is inherited in an autosomal recessive fashion and, although rare, is the most common genetic cause of childhood kidney failure.
Normal pressure hydrocephalus (NPH) is a particular form of chronic communicating hydrocephalus, characterized by enlarged cerebral ventricles, with only intermittently elevated cerebrospinal fluid pressure. Characteristic triad of symptoms are; dementia, apraxic gait and urinary incontinence.
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells. The most common side effects include fever, headache, increased levels of liver enzymes (a sign ...
The blue arrows indicate leucoaraiosis. In the left image these may well represent transependymal CSF diapedesis due to normal pressure hydrocephalus, which in turn is suggested by the narrowed superior CSF spaces and acute callosal angle. The unilateral occurrence of these alterations in right image suggests they are probably due to vascular ...
Niemann–Pick disease, type C1 NPH Normal pressure hydrocephalus: NTD Neural tube defect: NTDs Neural tube defects: NTDs Neglected tropical diseases: O. Acronyms
Nowadays, NPH is also called as "Hakim Syndrome" in honor of his accomplishments. [ citation needed ] Today, 9 to 14% of elderly living in any type of assisted facility suffered from NPH. [ 10 ] However, and despite the fact that this disorder was discovered in the late 1950s, and published in the mid 1960s, much more remains unknown, and NPH ...
The disease was renamed 'pantothenate kinase-associated neurodegeneration' or PKAN by Zhou et al. (2001) [3] who suggested the name to avoid misinterpretation and to better reflect the true nature of the disorder. Most recently Pellecchia et al. (2005) published a report of 16 patients affected by PKAN, confirmed by genetic analysis.